Iovance Biotherapeutics (NASDAQ:IOVA) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics (IOVA) Is Down 14.9% After Governance Scrutiny And Equity Raise Plan Is Revealed [Yahoo! Finance]
Iovance Biotherapeutics (IOVA) Valuation Check After Amtagvi Outlook Reaffirmation And Governance Concerns [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA): A Bull Case Theory [Yahoo! Finance]